Tango Therapeutics TNGX Q1 2026 earnings
Reported May 13, 2026 · Before market open
Revenue-
EPS-$0.32In line
EPS estimate-$0.32
Next report
Aug 4, 2026 (In 6 days)Revenue estimate$1.6M
EPS estimate-$0.31
Financials
Q1 2026Valuation & ratios
Versus estimates
Ask the moment Tango Therapeutics reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI

Claude
Questions, answered.
- When did Tango Therapeutics report Q1 2026 earnings?
- Tango Therapeutics (TNGX) reported Q1 2026 earnings on May 13, 2026 before market open.
- What were Tango Therapeutics's Q1 2026 revenue and EPS?
- Tango Therapeutics reported revenue of - and eps of $-0.32 for Q1 2026.
- Did Tango Therapeutics beat estimates in Q1 2026?
- EPS beat the consensus estimate of $-0.32 by $0.00.
- How did Tango Therapeutics's Q1 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 100.0% from $5.4M a year earlier and eps grew 11.1% from $-0.36.
- Where can I find Tango Therapeutics's Q1 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-221677) and the 10-Q periodic report (0001193125-26-221656) directly on SEC EDGAR. The filing index links above go to sec.gov.